Liang Anru, Wu Zuotao, Zhuo Ting, Zhu Yongjie, Li Zihao, Chen Sirong, Dai Lei, Wang Yongyong, Tan Xiang, Chen Mingwu
Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Clin Transl Oncol. 2025 Feb;27(2):518-533. doi: 10.1007/s12094-024-03627-w. Epub 2024 Aug 3.
The tonsoku-like DNA repair protein (TONSL) encoded by the TONSL gene, located on chromosome 8q24.3, is crucial for repairing DNA double-strand breaks through homologous recombination. However, TONSL overexpression in lung adenocarcinoma (LUAD) promotes tumor development, leading to a poor prognosis.
TONSL was verified as a reliable prognostic marker for LUAD using bioinformatics, and clinical features related to LUAD prognosis were screened from the TCGA database to establish the relationship between risk factors and TONSL expression. In addition, TONSL expression in normal and LUAD tissues was verified using real-time quantitative polymerase chain reaction and immunohistochemistry. To elucidate the possible functions of TONSL, TONSL-related differentially expressed genes were screened, and functional enrichment analysis was performed. Subsequently, siRNA was used to knock down TONSL expression in lung cancer cells for cytobehavioral experiments. The effects of TONSL expression on tumor immune escape were analyzed using the ESTIMATE algorithm and tumor immune-infiltration analysis. In addition, the half-maximal inhibitory concentration of LUAD with varying TONSL expression levels in response to first-line chemotherapeutic drugs and epidermal growth factor receptor-tyrosine kinase inhibitors was analyzed for drug sensitivity.
Up-regulation of TONSL in LUAD promotes the proliferation, migration, and invasion of lung cancer cells, thereby contributing to a poor prognosis. Furthermore, TONSL overexpression promotes immune escape and drug sensitivity in LUAD.
TONSL serves as a reliable prognostic marker for LUAD, and its up-regulation is associated with increased immune escape and drug sensitivity. These findings suggest that TONSL holds potential as a novel therapeutic target for LUAD.
位于染色体8q24.3的TONSL基因编码的类扁桃体DNA修复蛋白(TONSL)对于通过同源重组修复DNA双链断裂至关重要。然而,TONSL在肺腺癌(LUAD)中的过表达促进肿瘤发展,导致预后不良。
使用生物信息学验证TONSL是LUAD的可靠预后标志物,并从TCGA数据库中筛选与LUAD预后相关的临床特征,以建立危险因素与TONSL表达之间的关系。此外,使用实时定量聚合酶链反应和免疫组织化学验证正常组织和LUAD组织中TONSL的表达。为了阐明TONSL的可能功能,筛选了与TONSL相关的差异表达基因,并进行了功能富集分析。随后,使用小干扰RNA(siRNA)敲低肺癌细胞中TONSL的表达以进行细胞行为实验。使用ESTIMATE算法和肿瘤免疫浸润分析来分析TONSL表达对肿瘤免疫逃逸的影响。此外,分析了不同TONSL表达水平的LUAD对一线化疗药物和表皮生长因子受体酪氨酸激酶抑制剂的半数最大抑制浓度,以评估药物敏感性。
LUAD中TONSL的上调促进肺癌细胞的增殖、迁移和侵袭,从而导致预后不良。此外,TONSL过表达促进LUAD中的免疫逃逸和药物敏感性。
TONSL是LUAD的可靠预后标志物,其上调与免疫逃逸增加和药物敏感性相关。这些发现表明TONSL有望成为LUAD的新型治疗靶点。